Molecular features of giant-cell carcinoma of the lung: a case report and literature review

• Main Authors: Li X, Zhang ZH, Liu JH, Wang D, Wei S, Chen J
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-02-01
• Series: OncoTargets and Therapy
• Subjects: Giant cell carcinoma of the lung; High-throughput sequencing; gene mutation
• Online Access: https://www.dovepress.com/molecular-features-of-giant-cell-carcinoma-of-the-lung-a-case-report-a-peer-reviewed-article-OTT

Xin Li,* Zihe Zhang,* Jinghao Liu, Dan Wang, Sen Wei, Jun Chen Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China *These authors contributed equally to this work Abstract: Giant-cell carcinoma of the lung (GCCL) is a rare histological form of poorly differentiated non-small-cell lung cancer, which is classified as a subtype of pulmonary sarcomatoid carcinomas. In this case report, we describe the case of a 50-year-old Chinese male who presented with a pulmonary nodule in the right upper lobe of his lung. After thoracoscopic lobectomy, a histopathologic diagnosis of GCCL was made. He did well postoperatively, showing no local recurrence or distal disease in a 7-year follow-up period. Furthermore, for this case, we also analyzed 295 tumor-related driver genes with high-throughput sequencing technology. We found that treatment using MEK inhibitor, CDK 4/6 inhibitor, and TP53 inhibitor may provide a new therapeutic direction for GCCL. Therefore, complete tumor excision is the best choice of treatment strategy at the early stage of GCCL and gene target therapy may be a new therapeutic option for this disease. Keywords: giant-cell carcinoma of the lung, high-throughput sequencing, gene mutation